vs
亚什兰（ASH）与GE医疗（CCRN）财务数据对比。点击上方公司名可切换其他公司
亚什兰的季度营收约是GE医疗的1.6倍（$386.0M vs $236.8M），亚什兰净利率更高（-3.1% vs -35.0%，领先31.9%），亚什兰同比增速更快（-4.7% vs -23.6%），亚什兰自由现金流更多（$111.0M vs $16.1M），过去两年亚什兰的营收复合增速更高（-18.1% vs -21.0%）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
GE医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，品牌标识为GE HealthCare。公司主要业务分为四大板块：包含分子影像、CT、磁共振、妇科筛查及X光设备的医学影像业务、超声业务，以及聚焦远程患者监测、麻醉呼吸护理、心脏诊断、婴幼儿护理的患者护理解决方案业务，此外还开展医药相关业务。
ASH vs CCRN — 直观对比
营收规模更大
ASH
是对方的1.6倍
$236.8M
营收增速更快
ASH
高出18.9%
-23.6%
净利率更高
ASH
高出31.9%
-35.0%
自由现金流更多
ASH
多$94.9M
$16.1M
两年增速更快
ASH
近两年复合增速
-21.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $236.8M |
| 净利润 | $-12.0M | $-82.9M |
| 毛利率 | 27.2% | — |
| 营业利润率 | -1.6% | -30.2% |
| 净利率 | -3.1% | -35.0% |
| 营收同比 | -4.7% | -23.6% |
| 净利润同比 | 92.7% | -2109.7% |
| 每股收益（稀释后） | $-0.26 | $-2.56 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASHCCRN
| Q4 25 | $386.0M | $236.8M | ||
| Q3 25 | $477.0M | $250.1M | ||
| Q2 25 | $463.0M | $274.1M | ||
| Q1 25 | $479.0M | $293.4M | ||
| Q4 24 | $405.0M | $309.9M | ||
| Q3 24 | $521.0M | $315.1M | ||
| Q2 24 | $544.0M | $339.8M | ||
| Q1 24 | $575.0M | $379.2M |
净利润ASHCCRN
| Q4 25 | $-12.0M | $-82.9M | ||
| Q3 25 | $31.0M | $-4.8M | ||
| Q2 25 | $-742.0M | $-6.7M | ||
| Q1 25 | $31.0M | $-490.0K | ||
| Q4 24 | $-165.0M | $-3.8M | ||
| Q3 24 | $17.0M | $2.6M | ||
| Q2 24 | $6.0M | $-16.1M | ||
| Q1 24 | $120.0M | $2.7M |
毛利率ASHCCRN
| Q4 25 | 27.2% | — | ||
| Q3 25 | 33.3% | 20.4% | ||
| Q2 25 | 28.5% | 20.4% | ||
| Q1 25 | 30.7% | 20.0% | ||
| Q4 24 | 27.4% | — | ||
| Q3 24 | 33.2% | 20.4% | ||
| Q2 24 | 34.2% | 20.8% | ||
| Q1 24 | 28.0% | 20.4% |
营业利润率ASHCCRN
| Q4 25 | -1.6% | -30.2% | ||
| Q3 25 | 12.8% | -2.4% | ||
| Q2 25 | -152.9% | -2.1% | ||
| Q1 25 | 10.6% | -0.3% | ||
| Q4 24 | -44.2% | -1.1% | ||
| Q3 24 | 6.1% | 0.9% | ||
| Q2 24 | -11.2% | -5.7% | ||
| Q1 24 | 3.7% | 0.8% |
净利率ASHCCRN
| Q4 25 | -3.1% | -35.0% | ||
| Q3 25 | 6.5% | -1.9% | ||
| Q2 25 | -160.3% | -2.4% | ||
| Q1 25 | 6.5% | -0.2% | ||
| Q4 24 | -40.7% | -1.2% | ||
| Q3 24 | 3.3% | 0.8% | ||
| Q2 24 | 1.1% | -4.7% | ||
| Q1 24 | 20.9% | 0.7% |
每股收益（稀释后）ASHCCRN
| Q4 25 | $-0.26 | $-2.56 | ||
| Q3 25 | $0.83 | $-0.15 | ||
| Q2 25 | $-16.21 | $-0.20 | ||
| Q1 25 | $0.65 | $-0.02 | ||
| Q4 24 | $-3.50 | $-0.13 | ||
| Q3 24 | $0.34 | $0.08 | ||
| Q2 24 | $0.12 | $-0.47 | ||
| Q1 24 | $2.39 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $108.7M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $1.9B | $322.8M |
| 总资产 | $4.5B | $449.0M |
| 负债/权益比越低杠杆越低 | 0.74× | — |
8季度趋势，按日历期对齐
现金及短期投资ASHCCRN
| Q4 25 | $304.0M | $108.7M | ||
| Q3 25 | $215.0M | $99.1M | ||
| Q2 25 | $207.0M | $81.2M | ||
| Q1 25 | $168.0M | $80.7M | ||
| Q4 24 | $219.0M | $81.6M | ||
| Q3 24 | $300.0M | $64.0M | ||
| Q2 24 | $399.0M | $69.6M | ||
| Q1 24 | $439.0M | $5.2M |
总债务ASHCCRN
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | — |
股东权益ASHCCRN
| Q4 25 | $1.9B | $322.8M | ||
| Q3 25 | $1.9B | $408.1M | ||
| Q2 25 | $1.9B | $412.2M | ||
| Q1 25 | $2.6B | $418.2M | ||
| Q4 24 | $2.6B | $419.0M | ||
| Q3 24 | $2.9B | $424.7M | ||
| Q2 24 | $3.0B | $433.3M | ||
| Q1 24 | $3.1B | $462.4M |
总资产ASHCCRN
| Q4 25 | $4.5B | $449.0M | ||
| Q3 25 | $4.6B | $538.2M | ||
| Q2 25 | $4.6B | $553.8M | ||
| Q1 25 | $5.2B | $576.2M | ||
| Q4 24 | $5.2B | $589.3M | ||
| Q3 24 | $5.6B | $597.4M | ||
| Q2 24 | $5.7B | $602.9M | ||
| Q1 24 | $5.9B | $648.4M |
负债/权益比ASHCCRN
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.52× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 0.42× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | $18.2M |
| 自由现金流经营现金流 - 资本支出 | $111.0M | $16.1M |
| 自由现金流率自由现金流/营收 | 28.8% | 6.8% |
| 资本支出强度资本支出/营收 | 3.6% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $200.0M | $40.1M |
8季度趋势，按日历期对齐
经营现金流ASHCCRN
| Q4 25 | $125.0M | $18.2M | ||
| Q3 25 | $40.0M | $20.1M | ||
| Q2 25 | $115.0M | $4.2M | ||
| Q1 25 | $9.0M | $5.7M | ||
| Q4 24 | $-30.0M | $24.2M | ||
| Q3 24 | $80.0M | $7.5M | ||
| Q2 24 | $127.0M | $82.4M | ||
| Q1 24 | $54.0M | $6.0M |
自由现金流ASHCCRN
| Q4 25 | $111.0M | $16.1M | ||
| Q3 25 | $6.0M | $17.9M | ||
| Q2 25 | $95.0M | $2.3M | ||
| Q1 25 | $-12.0M | $3.8M | ||
| Q4 24 | $-53.0M | $21.7M | ||
| Q3 24 | $42.0M | $6.3M | ||
| Q2 24 | $98.0M | $79.6M | ||
| Q1 24 | $20.0M | $3.8M |
自由现金流率ASHCCRN
| Q4 25 | 28.8% | 6.8% | ||
| Q3 25 | 1.3% | 7.2% | ||
| Q2 25 | 20.5% | 0.8% | ||
| Q1 25 | -2.5% | 1.3% | ||
| Q4 24 | -13.1% | 7.0% | ||
| Q3 24 | 8.1% | 2.0% | ||
| Q2 24 | 18.0% | 23.4% | ||
| Q1 24 | 3.5% | 1.0% |
资本支出强度ASHCCRN
| Q4 25 | 3.6% | 0.9% | ||
| Q3 25 | 7.1% | 0.9% | ||
| Q2 25 | 4.3% | 0.7% | ||
| Q1 25 | 4.4% | 0.6% | ||
| Q4 24 | 5.7% | 0.8% | ||
| Q3 24 | 7.3% | 0.4% | ||
| Q2 24 | 5.3% | 0.8% | ||
| Q1 24 | 5.9% | 0.6% |
现金转化率ASHCCRN
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.71× | 2.92× | ||
| Q2 24 | 21.17× | — | ||
| Q1 24 | 0.45× | 2.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
CCRN
| Temporary Staffing Services | $189.6M | 80% |
| Physician Staffing | $42.5M | 18% |
| Other Services | $4.7M | 2% |
